- Home
- ERAS vs CRML Comparison
ERAS vs CRML Comparison
Compare ERAS & CRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- CRML
- Stock Information
- Founded
- ERAS 2018
- CRML N/A
- Country
- ERAS United States
- CRML United States
- Employees
- ERAS N/A
- CRML N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- CRML
- Sector
- ERAS Health Care
- CRML
- Exchange
- ERAS Nasdaq
- CRML NYSE
- Market Cap
- ERAS 723.8M
- CRML 604.3M
- IPO Year
- ERAS 2021
- CRML N/A
- Fundamental
- Price
- ERAS $1.90
- CRML $7.95
- Analyst Decision
- ERAS Strong Buy
- CRML
- Analyst Count
- ERAS 5
- CRML 0
- Target Price
- ERAS $5.70
- CRML N/A
- AVG Volume (30 Days)
- ERAS 1.5M
- CRML 85.4K
- Earning Date
- ERAS 11-12-2024
- CRML 02-01-2025
- Dividend Yield
- ERAS N/A
- CRML N/A
- EPS Growth
- ERAS N/A
- CRML N/A
- EPS
- ERAS N/A
- CRML N/A
- Revenue
- ERAS N/A
- CRML $117,660.00
- Revenue This Year
- ERAS N/A
- CRML N/A
- Revenue Next Year
- ERAS N/A
- CRML N/A
- P/E Ratio
- ERAS N/A
- CRML N/A
- Revenue Growth
- ERAS N/A
- CRML 5.79
- 52 Week Low
- ERAS $1.64
- CRML $5.32
- 52 Week High
- ERAS $3.45
- CRML $22.50
- Technical
- Relative Strength Index (RSI)
- ERAS 29.70
- CRML 57.51
- Support Level
- ERAS $1.77
- CRML $7.29
- Resistance Level
- ERAS $2.84
- CRML $9.89
- Average True Range (ATR)
- ERAS 0.18
- CRML 0.96
- MACD
- ERAS -0.07
- CRML 0.13
- Stochastic Oscillator
- ERAS 12.15
- CRML 42.77
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About CRML CRITICAL METALS CORPORATION
Critical Metals Corp is engaged in lithium exploration in Austria. It is focused on the development of its wholly-owned Wolfsberg Lithium Project (the Wolfsberg Project) located in Carinthia, Austria.